1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > EpiCast Report: Type 1 Diabetes - Epidemiology Forecast to 2023

EpiCast Report: Type 1 Diabetes - Epidemiology Forecast to 2023

Summary

Type 1 diabetes is a type of diabetes that accounts for 10% of all diabetes cases. The condition occurs as a result of the autoimmune destruction of pancreatic beta cells, which are responsible for producing insulin - a hormone that regulates blood sugar. Type 1 diabetes, formerly referred to as insulin-dependent diabetes, mostly develops in children and young adults. Hence, it has also been called juvenile diabetes, although this term is no longer frequently used.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of type 1 diabetes in the 8MM. The diagnosed prevalent cases of type 1 diabetes in the 8MM will grow by 40.40% over the next decade, from 6.02 million prevalent cases in 2013 to 8.45 million prevalent cases in 2023.

To forecast the diagnosed prevalent cases of type 1 diabetes in the 8MM, GlobalData epidemiologists selected nationally representative population-based studies that provided diagnosed prevalence data in the 8MM. Furthermore, GlobalData epidemiologists segmented the prevalent cases of type 1 diabetes by BMI in each market. These BMI segmentations could provide valuable insight into potential patient populations that are eligible for targeted screening programs.

Scope

- The Type 1 Diabetes EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for type 1 diabetes in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada). In addition, the report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of type 1 diabetes segmented by age (ages 0-14 years,15-29 years, 30-44 years, 45-59 years, 60-74 years, and =75 years) and sex. Furthermore, the report provides the distribution of diagnosed prevalent cases of type 1 diabetes segmented by body mass index (BMI) (kg/m2) (BMI <20, BMI 20-<25, BMI 25-<30, BMI =30) in these markets.
- The Type 1 Diabetes epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global type 1 diabetes market.
- Quantify patient populations in the global type 1 diabetes market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups, sex that present the best opportunities for type 1 diabetes therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Type 1 Diabetes - Epidemiology Forecast to 2023
1 Table of Contents

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 7
2.3 Upcoming Related Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 11
3.3.1 US 12
3.3.2 5EU 12
3.3.3 Japan 13
3.3.4 Canada 14
3.4 Forecast Methodology 14
3.4.1 Sources Used 16
3.4.2 Sources Not Used 19
3.4.3 8MM, Forecast Assumptions and Methods - Diagnosed Prevalent Cases of Type 2 Diabetes in Persons Ages ?20 Years 20
3.4.4 8MM, Forecast Assumptions and Methods - Diagnosed Prevalent Cases of Type 1 Diabetes 23
3.5 Epidemiological Forecast for Type 1 Diabetes (2013-2023) 29
3.5.1 Diagnosed Prevalent Cases of Type 1 Diabetes 29
3.5.2 Age-Specific Diagnosed Prevalent Cases of Type 1 Diabetes 31
3.5.3 Sex-Specific Diagnosed Prevalent Cases of Type 1 Diabetes 32
3.5.4 Age-Standardized Diagnosed Prevalence of Type 1 Diabetes 34
3.5.5 Diagnosed Prevalent Cases of Type 1 Diabetes Segmented by Body Mass Index (BMI) 36
3.6 Discussion 37
3.6.1 Epidemiological Forecast Insight 37
3.6.2 Limitations of the Analysis 38
3.6.3 Strengths of the Analysis 39
4 Appendix 40
4.1 Bibliography 40
4.2 About the Authors 44
4.2.1 Epidemiologists 44
4.2.2 Reviewers 44
4.2.3 Director of Epidemiology 46
4.2.4 Global Head of Healthcare 47
4.3 About GlobalData 47
4.4 About EpiCast 48
4.5 Disclaimer 48

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Type 1 Diabetes 11
Table 2: 8MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of Type 1 Diabetes 15
Table 3: 8MM, Sources of Epidemiological Data Used for the Prevalent Cases of Type 1 Diabetes Segmented by BMI 15
Table 4: 8MM, Sources Not Used in the Epidemiological Analysis of Type 1 Diabetes 20
Table 5: 8MM, Diagnosed Prevalent Cases of Type 1 Diabetes, All Ages, Both Sexes, N, 2013-2023 30
Table 6: 8MM, Diagnosed Prevalent Cases of Type 1 Diabetes, by Age, Both Sexes, N (Row %), 2013 31
Table 7: 8MM, Diagnosed Prevalent Cases of Type 1 Diabetes, by Sex, All Ages, N (Row %), 2013 33

1.2 List of Figures

Figure 1: 8MM, Diagnosed Prevalent Cases of Type 1 Diabetes, All Ages, Both Sexes, N, 2013-2023 30
Figure 2: 8MM, Diagnosed Prevalent Cases of Type 1 Diabetes, by Age, Both Sexes, N, 2013-2023 32
Figure 3: 8MM, Diagnosed Prevalent Cases of Type 1 Diabetes, by Sex, All Ages, N, 2013 34
Figure 4: 8MM, Age-Standardized Diagnosed Prevalence (%) of Type 1 Diabetes, All Ages, by Sex, 2013 35
Figure 5: 8MM, Diagnosed Prevalent Cases of Type 1 Diabetes, All Ages, by BMI (kg/m2), 2013 36

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Type 1 Diabetes (Juvenile Diabetes)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Type 1 Diabetes (Juvenile Diabetes)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

  • $ 2000
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Report, “Type 1 Diabetes (Juvenile Diabetes)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug ...

 Type 1 Diabetes (Juvenile Diabetes)-API Insights, 2016

Type 1 Diabetes (Juvenile Diabetes)-API Insights, 2016

  • $ 1250
  • Industry report
  • November 2016
  • by Delve Insight

The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuste ...

Global Diabetes Diagnostics Industry

Global Diabetes Diagnostics Industry

  • $ 4950
  • Industry report
  • October 2016
  • by Global Industry Analysts

This report analyzes the worldwide markets for Diabetes Diagnostics in US$ Thousand by the following Product Segments: Continuous Glucose Monitoring (CGM) Systems, HbA1c Testing Devices, and Blood Glucose ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.